Led · Series C · Aug 2026

Skan AI builds a continuously evolving record of how work actually happens across enterprise systems, distilling billions of observed work signals into execution logic for AI. Its platform consists of Skan AI Blueprint (discovery and prioritization of AI opportunities), Skan AI Intelligence (process benchmarking and workforce management), and Skan AI Agents (agent execution grounded in observed work). The company reports it has processed over 25 billion work signals, is trusted by a quarter of the Fortune 50 and seven of the top ten U.S. banks, and has delivered more than $500 million in cumulative customer value. Skan AI reported more than 300% year-over-year growth and average net dollar retention of 150% in the past year. The company says customers realize average operational savings of 30–40% from deployments. The business targets complex, regulated workflows in industries such as banking, insurance, and healthcare, and is based in Menlo Park, Calif.

Participated · Series D · Jun 2026

TISSIUM is a clinical and commercial-stage MedTech company founded in 2013 that develops fully biosynthetic, biomorphic, programmable elastomeric polymers for atraumatic tissue repair and tissue reconstruction. The company’s first commercial product, COAPTIUM® CONNECT, received FDA marketing authorization and TISSIUM has entered the U.S. commercial market. Its diversified pipeline includes one commercial product and six products in development across three core verticals: atraumatic sutureless nerve repair, atraumatic hernia repair, and cardiovascular sealants. TISSIUM pairs its polymer solutions with specialized delivery and activation devices designed to optimize procedure consistency and usability. The company is based in Paris and Cambridge and operates a manufacturing site in Roncq, France. Recent financing provides capital to support commercial rollout, advance multiple clinical programs and continue expanding its proprietary biomorphic polymer platform.

Participated · Series A · Jun 2026

Theker develops AI-native generalist robots designed to operate autonomously and adapt in real time to changing industrial environments. Its technology targets industries such as logistics, retail, food and beverage, and waste management and is being deployed to address labour shortages in manufacturing and retail. The company positions its robots as a new category compared with traditional rigid, task-specific industrial robots. Founded in 2022 and based in Barcelona, Theker has raised €18 million in seed funding and an $85 million Series A. The firm plans to use the new capital to accelerate deployments with industrial operators, deepen its proprietary AI and robotics stack, and expand engineering and deployment teams.

Led · Series B · May 2026

Embat builds AI-driven treasury management software and an agentic AI analyst called TellMe that detects cash flow patterns, automates complex reconciliations and suggests decisions to optimise liquidity. The platform centralises financial operations in real time via hybrid connectivity to over 15,000 banks and major ERPs. Embat serves roughly 400 corporate clients across Europe and says its AI technology can automate up to 80% of manual treasury tasks. The company was founded in 2021 by Antonio Berga, Carlos Serrano and Tomás Gil and now employs about 150 people. Its client roster includes Treatwell, Northern Data, Fever, PetLab Co., International Schools Partnership, Derwent and Arena Racing Company. Embat plans to use its new funding to expand its presence in the UK and Ireland, grow its team and accelerate go-to-market efforts.

Participated · Series B · Mar 2026

Qualified Health provides a secure enterprise AI platform and strategic services to help health systems deploy AI with embedded safety, governance, and monitoring. Its platform combines workflow automation, agent development, clinical safeguards, real-time monitoring, and end-to-end traceability. Early deployments with partners including Mercy, Emory Healthcare, University of Rochester Medicine, Jefferson Health, and the University of Texas System have produced measurable revenue uplift and cost savings, including more than $15 million in run-rate impact at UTMB within six months. The platform currently supports more than 500,000 users across health systems representing approximately 7% of U.S. hospital revenue. The company is led by former health system executives, frontline physicians, clinical transformation experts, and Silicon Valley engineers. Qualified Health plans to deepen partnerships and scale its platform responsibly while expanding governance, monitoring, and infrastructure to support mission-critical AI deployments.